US FDA Emphasizes Primary Endpoint Primacy In Vatiquinone, Lytenava CRLs

 
• By Bridget Silverman
  
The US FDA snuffed the approval hopes of PTC's vatiquinone, Outlook Therapeutics' Lytenava, and Telix's Zircaix. (Shutterstock)

More from Complete Response Letters

More from Product Reviews